title: Management of T2 esophageal cancer.
abstract: Patients with clinically staged T2N0 esophageal cancer are a small subset of patients for whom therapy is not standardized. Current clinical staging modalities are lacking in providing accurate staging for the presumed T2N0 subset. Problems with overstaging and understaging can each have adverse consequences for the patient. Furthermore, the benefit of induction therapy versus esophagectomy followed by adjuvant therapy for upstaged patients is unproven. The management of this challenging group of patients is reviewed.
authors.affiliation: Division of Cardiothoracic Surgery, Emory University School of Medicine, Emory University Hospital, Atlanta, GA 30322, USA.
authors.forename: Manu
authors.initials: M
authors.lastname: Sancheti
authors.forename: Felix
authors.initials: F
authors.lastname: Fernandez
mesh_terms: D059186:Chemoradiotherapy, Adjuvant; D061765:Endoscopic Ultrasound-Guided Fine Needle Aspiration; D019160:Endosonography; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000628:therapy; D016629:Esophagectomy; D004945:Esophagoscopy; D006801:Humans; D008207:Lymphatic Metastasis; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed